Insulet CorporationNasdaq: PODD
Health Care · Health Care Equipment
$145.72
+1.53%
Vol: 999K
Research Digest
Friday, June 19, 2026
Insulet expands Omnipod 5 with Abbott Libre 3 Plus compatibility while managing a 7 million pod recall and up to $50M in non-GAAP charges.
Insulet Corporation announced the U.S. rollout of enhanced algorithm updates for the Omnipod 5 Automated Insulin Delivery System following December 2025 FDA clearance, and added integration with Abbott's Libre 3 Plus continuous glucose monitor. However, the company disclosed a voluntary recall of approximately 7 million Omnipod insulin pods due to a manufacturing defect, along with up to $50 million in non-GAAP charges mostly concentrated in Q2 2026, causing PODD shares to drop more than 7% on the announcement. Management reaffirmed 2026 guidance and its 2026-2028 financial targets, which helped limit further selloff. A board director, Elizabeth H. Weatherman, purchased nearly $500,000 of PODD shares on June 3, 2026, signaling insider confidence. Analyst views are mixed, with RBC maintaining Outperform at $280, BTIG holding Buy at $235, and Goldman Sachs cutting to $205 from $237.
Previous Market Intelligence
13 daysJun 18No significant overnight updatesNeutral▶
No material news in the last 48 hours.
Jun 17No significant overnight updatesNeutral▶
No material news in the last 48 hours.
Jun 16No significant overnight updatesNeutral▶
No material news in the last 48 hours.
Jun 15No significant overnight updatesNeutral▶
No material news in the last 48 hours.
Jun 14No significant overnight updatesNeutral▶
No material news in the last 48 hours.
May 21William Blair assumed coverage of Insulet with Outperform on May 20, but PODD shares fell to ~$290 in after-hours after closing at $314.18 amid concerns following the annual meeting.Mixed▶
On May 20, 2026, William Blair analyst Steve Lichtman assumed coverage of Insulet (PODD) with an Outperform rating. The same day, Insulet held its 2026 Annual Meeting of Shareholders virtually at 8:00 a.m. ET. Despite the bullish initiation, PODD closed at $314.18 and then dropped to approximately $290 in after-hours trading, extending a sharp pullback — shares are down about 25% over the past month and 38% over three months despite a strong Q1 2026 report (revenue +33.9% y/y to $761.7M, non-GAAP EPS of $1.42 beating by 19.3%). Year-to-date the stock is off 46.1% and trailing 1-year return is -53.2%. Q2 revenue guidance of $785.4M came in 0.8% below consensus, weighing on sentiment.
May 20Insulet held its 2026 annual shareholder meeting on May 20 following Q1 beat but faces price target cuts from Goldman Sachs and BofA.Mixed▶
Insulet held its 2026 annual shareholder meeting on May 20, 2026, via virtual webcast. Q1 2026 results released May 6 showed revenue up 33.9% YoY to $761.7M, beating estimates, with non-GAAP EPS of $1.42 (19.3% above consensus); management raised 2026 revenue growth and operating margin guidance by 100bps at the midpoint. Despite the beat, stock has been volatile - down about 25% over the past month and 38% over three months. Goldman Sachs cut its price target to $237 from $277 (Buy maintained), and Bank of America cut its PT to $208 from $288 in mid-May. Benchmark issued a Buy with $250 PT amid Riyadh regional HQ opening. Insulet also participated in the BofA Securities Healthcare Conference on May 13.
May 19Insulet shares fell 6% on May 13 to $148.84 (down 44% YTD) despite Q1 revenue of $761.7M (+34% YoY) beating estimates, with Goldman trimming PT to $237 and Benchmark initiating Buy at $250.Mixed▶
Insulet reported Q1 CY2026 revenue of $761.7M, up 33.9% year-over-year and beating Wall Street expectations, with non-GAAP EPS of $1.42, 19.3% above consensus. Management raised its 2026 revenue growth and operating margin outlook by 100 bps at the midpoint. Despite the beat, next-quarter revenue guidance of $785.4M came in 0.8% below consensus and the stock fell 6% on May 13 to $148.84, now down 43.9% YTD and 55% off its 52-week high of $352.82. Benchmark issued a Buy rating with a $250 PT and the company opened a new MENA regional HQ in Riyadh; Goldman Sachs trimmed its PT to $237 while keeping Buy. Insulet's annual shareholder meeting is May 20, 2026, and management presented at the BofA Healthcare Conference on May 13.
May 18No significant overnight updatesNeutral▶
No material news in the last 48 hours.
May 15Insulet raises FY26 sales guidance to 21-23% growth with Q1 revenue up 33.9% to $761.7M; Benchmark initiates Buy at $250.Positive▶
Insulet reported Q1 2026 revenue of $761.7 million, up 33.9%, with EPS of $1.30. The company raised full-year 2026 guidance to 21-23% sales growth and expects adjusted EPS to exceed $6.25 per share. Operating margins expanded to 17.5%. On May 4, 2026, Insulet enrolled the first participant in its EVOLVE pivotal trial for a fully closed-loop insulin delivery system for type 2 diabetes. The company opened its Middle East and North Africa regional headquarters in Riyadh, Saudi Arabia. On May 12, shares jumped 3.4% after Benchmark initiated coverage with a Buy rating and $250 price target. Despite these positives, the stock is down 43.9% YTD at $158.82, trading 55% below its September 2025 high.
May 14Multiple Wall Street firms slashed Insulet price targets in May after Q1 results, signaling concerns about valuation despite strong Omnipod 5 growthMixed▶
In early May 2026, several analysts cut price targets on Insulet: Goldman Sachs to $237 from $277, Raymond James to $263 from $355, RBC Capital to $280 from $325, Bernstein to $200 from $330, Canaccord to $249 from $435, and Baird to $248 from $360. The cuts followed Q1 2026 results showing revenue up 33.9% YoY to $762M and adjusted EPS of $1.42 beating $1.18 estimates. Despite raised full-year guidance to 21-23% sales growth and adjusted EPS above $6.25, the stock has fallen sharply year-to-date to $158.92, near its 52-week low of $148.31. The price target cuts reflect concerns about decelerating growth and rising costs even as Omnipod 5 adoption remains strong. Risk: continued multiple compression if growth normalizes faster than expected.
May 13Insulet shares jumped 3.4% on May 12, 2026 after Benchmark initiated coverage with a Buy rating and $250 price target, plus a new MENA HQ announcement in Riyadh.Positive▶
Insulet Corporation shares jumped 3.4% on May 12, 2026 after Benchmark initiated coverage with a Buy rating and a $250 price target, sending a bullish signal on the insulin delivery leader. The same day, Insulet announced the opening of its Middle East and North Africa regional headquarters in Riyadh, Saudi Arabia, marking a strategic expansion to manage operations and partner development in a high-growth diabetes market. Management is also scheduled to present at the BofA Securities 2026 Health Care Conference on May 13, 2026. The new coverage comes after the company recently raised 2026 revenue guidance to 21%-23% growth following Q1 revenue of $761.7 million (+33.9% YoY). Risk remains around the ongoing Omnipod 5 tubing recall, with 29 serious injuries reported as of April 17, and a 41.1% YTD stock decline despite strong fundamentals.
May 12No significant overnight updatesNeutral▶
No material news in the last 48 hours.
Sector Peers
| Company | Price | Day | 1M | Fwd P/E | Beta | Mkt Cap |
|---|---|---|---|---|---|---|
| PODDINSULET | $145.72 | +1.53% | — | 20.4x | 1.11 | $11.4B |
| ABTABBOTT | $88.64 | +0.16% | — | 15.8x | 0.61 | $166.2B |
| ISRGINTUITIVE | $406.90 | +1.17% | — | 36.1x | 1.46 | $150.9B |
| SYKSTRYKER | $309.23 | +2.68% | — | 19.5x | 0.78 | $125.2B |
| MDTMEDTRONIC | $79.43 | +1.64% | — | 13.0x | 0.58 | $106.5B |
Key Fundamentals
RSI (14-Day)
52-Week Range
Moving Averages
Price below 200d MA — bearish structure.